Akt and cyclin D1 in a variety of lymphoma cell lines SeveSeveral clinical responses were observed in a phase II study of 17 patients with AAG R / R MCL or HL. SNX 2112 was found to have effects rituximabresistant in combination with bortezomib and Cilomilast rituximab in NHL cell lines. SNX 2112 is currently in Phase I clinical trials. 5.10. Angiogenesis. Tumor angiogenesis is important in a variety of malignant diseases. Bevacizumab has been extensively studied in solid tumors evaluated in lymphoma. In a phase II study of the SWOG RCHOP plus bevacizumab in patients with advanced DLBCL was observed 1 year PFS hen Sch Estimation rather increased the historical to Sch Catalyst. However, as significant toxicity t With the addition of bevacizumab was associated regime have not been recommended for evaluation. In a Phase II trial of sunitinib monotherapy in R / R DLBCL was no evidence of activity Recorded and t h Hematological toxicity Were th h Her than expected. The fusion protein of Vaskul Ren endothelial growth factor H Half, aflibercept was evaluated in a Phase I trial in combination with CHOP-R in untreated patients with bilateral credit lines.
6 mg / kg dose of aflibercept in all phase III trials underway used in other indications, and the combination with CHOP-R has entered Born high response rates in this study. The major events of grade 3 or 4 adverse MDV3100 events hypertension, febrile neutropenia, and asthenia. Preferences INDICATIVE results from two recent phase II studies with sorafenib. In a study of monotherapy in heavily pretreated patients with R / R NHL, were a series of reactions observed and the treatment was generally well tolerated. In a phase II study of perifosine in combination with Akt inhibitor in R / R’s lymphomas, were a series of PR with thrombocytopenia the h Most common drug-h Hematological toxicity Observed t. A phase II trial in relapsed DLBCL is currently underway. The combination of sorafenib and everolimus has been shown well tolerated possible to change with the observed activity of t, especially in HL in a Phase I trial in patients with lymphoma or MM 5.
11. Other targeted drugs and new therapies. Farnesyltransferase the most important enzymes in cellular Ren protein prenylation involved. Prenylated proteins Are important for the growth of b Sartigen cells. The oral inhibitor of farnesyl transferase, tipifarnib was evaluated in a Phase II trial in patients with relapsed, aggressive, or rare indolent lymphomas. Tipifarnib had good reps Opportunity and showed activity t in lymphoma, with responses in heavily pretreated patients with DLBCL, HL and types of T cells, although some activity t In follicular Ren NHL was observed. MLN4924 is an inhibitor of Nedd8-activating enzyme, which plays an r Crucial role in regulating the activity of t Cullin E3 ligases of the RING. Pr Clinical activity T was detected in a new model of primary Ren human DLBCL xenograft and a Phase 1 multiple doseescalation regime is underway in patients with R / R MM or lymphoma. M Possible molecular targets for new treatments begin, an emerging field of biology lymphomas are identified with energy metabolism.